A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Public ClinicalTrials.gov record NCT05319730. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B
Study identification
- NCT ID
- NCT05319730
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 230 participants
Conditions and interventions
Conditions
Interventions
- Acetaminophen (or equivalent) Drug
- Antihistamine Drug
- Dexamethasone (or equivalent) Drug
- H2 Receptor Antagonist Drug
- Irinotecan Drug
- Lenvatinib Drug
- MK-4830 Biological
- Paclitaxel Drug
- Pembrolizumab Biological
- Sacituzumab tirumotecan Biological
- Steroid Mouthwash (dexamethasone or equivalent) Drug
- Supportive care measures Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 15, 2023
- Primary completion
- Jun 10, 2027
- Completion
- Apr 9, 2029
- Last update posted
- Mar 19, 2026
2023 – 2029
United States locations
- U.S. sites
- 5
- U.S. states
- 4
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927) | Tucson | Arizona | 85719 | Recruiting |
| UCLA Hematology/Oncology - Santa Monica ( Site 4905) | Los Angeles | California | 90404 | Recruiting |
| Hematology-Oncology Associates of Central NY, P.C. ( Site 4925) | East Syracuse | New York | 13057 | Recruiting |
| Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907) | New York | New York | 10032 | Completed |
| UPMC Hillman Cancer Center-UPMC ( Site 4904) | Pittsburgh | Pennsylvania | 15232 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05319730, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2026 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05319730 live on ClinicalTrials.gov.